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Urinary/Kidney disorders – Patient-reported outcomes & Patient Preference 
studies
PUK25
imPlications of non-adherence to PhosPhate Binders on Patients’ 
PhosPhate levels
Furniss S.J.1, Lim A.2, Phillips Z.3
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Objectives: Elevated serum phosphate (hyperphosphataemia) usually accom-
panies end-stage renal disease and results from the inability of damaged kidneys 
to effectively regulate phosphate levels. Failure to maintain adequate phosphate 
balance has important clinical consequences, with an increased morbidity and 
risk of mortality. When dietary phosphate restriction is inadequate for control, 
administration of phosphate binders may be required. A number of phosphate 
binders are currently available; however, these often require high doses to control 
serum phosphate levels and this may result in lowered patient compliance. The 
objectives of this research were to assess the pill burden associated with phos-
phate binders and highlight any links between pill burden, patient adherence and 
outcomes in terms of serum phosphate levels. MethOds: A literature review 
was performed using the PubMed database using the search term “phosphate 
binders AND adherence”. Twenty six articles were identified in total, with ten 
relevant articles. Results: Six of the ten relevant articles (60%) found that low 
patient adherence or high pill burden were associated with higher mean serum 
phosphate level, whereas only one article (10%) concluded that no link existed. 
Seven articles reported dose increases with phosphate binder treatment or an 
increased number of pills per patient per day over the treatment course, with two 
reporting that the actual dose of phosphate binders in clinical practice was higher 
than those recommended in clinical guidelines. A high pill burden was found to 
lead to low adherence by three of the articles identified (30%), whereas only one 
of the papers identified did not support this hypothesis (10%). cOnclusiOns: 
This research indicates that there is a high pill burden associated with phosphate 
binders, as well as a requirement in clinical practice for high dosages. There is 
a suggestion that these factors are linked to low patient adherence and poorer 
control of serum phosphate levels.
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Objectives: Health economic evaluations of therapeutic interventions in patients 
with CKD and SHPT requiring dialysis (CKD-SHPT) should incorporate the impact of 
major clinical events related to their disease. However, little is known about the disu-
tility (i.e, utility decrease) associated with cardiovascular (CV) and fracture events in 
the context of CKD-SHPT. The purpose of this study was to estimate, via preference-
based valuation completed by general population respondents, the added disutil-
ity of these events beyond the impact of CKD-SHPT. MethOds: One-year health 
states were developed describing CKD-SHPT and related CV/fracture acute events/
procedures. Events with long-term effects (post one year) were also captured in 
chronic health states. General population participants in Canada completed time 
trade-off (TTO) interviews to assess health state utilities. Respondents initially rated 
the CKD-SHPT health state. Then, events and procedures were added to this health 
state: myocardial infarction (MI); unstable angina (UA); heart failure exacerbation; 
peripheral vascular disease (PVD) ± amputation; stable angina (SA); stroke; hip/arm 
fractures; parathyroidectomy; kidney transplant. Each participant was randomly-
assigned 11 of 16 health states to rate. Results: A total of 199 participants (54.8% 
female; mean age = 46.3 years) completed interviews. Each health state had ≥ 130 
valuations. CKD-SHPT had a mean utility of 0.60 (SD= 0.34). For acute events, mean 
utility decrements additional to CKD-SHPT were: MI, -0.06; UA, -0.05; PVD with 
amputation, -0.33; PVD without amputation, -0.11; heart failure, -0.14; stroke -0.30; 
hip fracture, -0.14; arm fracture, -0.04; parathyroidectomy, +0.02; kidney transplant, 
+0.06. Disutilities for chronic effects were: SA, -0.09; stroke -0.27; PVD with ampu-
tation -0.30; PVD without amputation, -0.12; heart failure, -0.14. cOnclusiOns: 
Valuation of health states representing CKD-SHPT plus major clinical events was 
feasible using TTO with a one-year time horizon. These data will assist investiga-
tors in applying appropriate disutilities to clinical events in economic evaluations 
of treatments for patients with CKD-SHPT requiring dialysis.
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Objectives: To determine the impact of sacral neuromodulation (SNM) on EQ-5D 
index scores and OAB management costs using an Economic Impact Questionnaire 
(EIQ) in patients who failed at least one anticholinergic medication enrolled in the 
InSite study, an ongoing, prospective, multicenter trial of SNM. MethOds: EQ-5D 
and EIQ were administered at baseline, 3-, 6- and 12-months post-implant. OAB-
related expenses included durable and disposable medical supplies and health 
service utilization (emergency room, hospitalizations and outpatient). A total of 340 
Objectives: Mirabegron is a first-in-class beta-3 adrenoceptor agonist for the 
treatment of overactive bladder (OAB) that demonstrated superior efficacy com-
pared to placebo by reducing OAB symptoms and improving HRQoL. We sought 
to assess the cost-effectiveness of mirabegron 50 mg in comparison with current 
antimuscarinics for the treatment of patients with OAB in the UK. MethOds: 
A Markov model was developed to simulate the therapeutic management, the 
changes in symptoms (micturitions and incontinence), and complications in 
hypothetical cohorts of OAB patients. The model was used to predict costs and 
QALYs over 5 years in cohorts initially treated with antimuscarinics or mirabe-
gron 50mg. Effectiveness and safety data were based on the results from a mixed 
treatment comparison (MTC). A calibration approach was used to derive transition 
probabilities from mean changes in frequency of micturitions and incontinence 
episodes. Other input data were obtained from several sources, including scien-
tific literature and expert opinions. Costs were evaluated from the UK National 
Health Service (NHS) perspective and included costs of drug acquisition, GP visits, 
specialist visit, incontinence pad use and botox injections. Utilities were obtained 
from equations predicting EQ-5D index scores according to symptom severity, 
estimated from a clinical trial of Mirabegron. Results: The Mirabegron strategy 
was slightly more expensive and associated with a greater number of QALYs, as a 
result of improved persistence, related to a lower risk of adverse event compared 
to each antimuscarinic. Mirabegron 50mg was found to be cost-effective com-
pared to each antimuscarinic, with an ICER of £340 vs. solifenacin 10mg, £3,607 
versus fesoterodine 4mg, £3,715 vs. tolterodine ER 4mg, £3,878 vs. oxybutynin ER 
10mg, £8,881 versus trospium chloride MR 60 mg, £12,493 versus solifenacin 5mg, 
and £14,234 oxybutynin IR 10mg. cOnclusiOns: Treatment with mirabegron 
appears to be a cost-effective strategy compared with antimuscarinics from a 
UK NHS perspective.
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Objectives: Intravenous (IV) irons are second line treatments for iron deficien-
cies in severe chronic kidney disease (CKD) patients with iron deficiency anaemia. 
Aim of this study was to compare ferumoxytol, a new agent, against IV ferric 
carboxymaltose (FC) and IV iron sucrose (IS), from a Belgian health care payer (BP) 
and hospital perspective (HP). MethOds: The CKD patients were categorized in 
haemodialysis (HD), peritoneal dialysis (PD), non-dialysis (post-renal transplant 
and non-dialysis) and all patients combined. The available IV irons have a simi-
lar efficacy. Adverse events were not included due to missing comparative data 
and low rates. However, the administration time and number of administrations 
differ among treatments. So a cost-minimization analysis was conducted (time 
horizon: 1 year). The average annual need of IV Iron is 3,500 mg in HD, 2,500 mg in 
PD and 1,500 mg in non-dialysis patients. The hospital perspective was modelled 
by deducting the nurse time cost from the hospital fee per administration (HP). 
For the health care payer the administration cost (hospital fee) and the drug costs 
are included (BP). Other costs were excluded because they did not affect the incre-
mental cost of treatment. Results: The total cost (euro 2012) for all patients was 
€ 676.57, € 819.82 and € 617.34 for ferumoxytol, FC and IS, respectively (BP). In the 
renal transplant and non-dialysis subgroups, ferumoxytol is less costly than FC 
and IS (BP). In the HD subgroup (86.77% of all eligible patients), IS is the least costly 
option (BP). The hospital cost in all patients is higher with IS due to more nurse 
time (€ 101.31, € 7.58 and € 144.19 for ferumoxytol, FC and IS) (HP). cOnclusiOns: 
Hospitals benefit from lower administration costs with ferumoxytol and FC (HP). 
From a Belgian payer perspective, ferumoxytol is less costly than FC and more 
costly than IS.
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Objectives: Anaemia is a frequent complication among patients with Chronic 
Kidney Disease (CKD) and is associated with poor outcomes. European data on the 
patterns of treatment of anaemia in non-dialysed (ND) CKD patients are scarce. 
The aim of this study was to describe the anaemia-associated Health Resource 
Utilization (HRU) in an Italian cohort of ND-CKD patients. MethOds: The admin-
istrative data and clinical laboratory files of 5 Italian Local Health Units from 2006 
to 2011 were used to identify ND patients with CKD (stage3b, 4, 5) and anemia. 
Anaemia-related HRU and associated costs were investigated. Results: A total 
of 1175 patients were included; 790 in CKD stage 3b; 331 in stage 4; 54 in stage 5. 
Anaemia-related medications were prescribed to 31.9% of patients and the per-
centage increased along the CKD stages from 28.9% for stage 3b to 42.6% for stage 
5. Among the drug-treated patients Erythropoiesis-stimulating agents were pre-
scribed to 82.6% of CKD stage 5 patients whereas CKD stage 3b patients received 
mostly oral iron (59.6%). Patients receiving any anaemia-related medications 
had lower per patient-per year cost for almost all studied resources compared to 
patients not receiving any medications. For anaemia-related outpatient services 
[drug-treated and not drug-treated]: stage 3b costs per patient year were € 62.12 
and € 62.32 respectively; stage 4 costs were € 52.23 and € 72.76; stage 5 costs were 
€ 55.83 and € 83.08. For general visits: stage 3b costs were € 168.51 and € 170.28; stage 
4 costs were € 124.17 and € 173.79; stage 5 costs were € 134.49 and € 343.63. For CV 
hospitalizations: stage 3b costs were € 1378.63 and € 1828.60; stage 4 costs were 
€ 1185.17 and € 2155.82; stage 5 costs were € 521.61 and € 514.63. cOnclusiOns: 
Among ND CKD patients drug treatment may help control anaemia-related outpa-
tient services and contain CV hospitalization costs and represents an opportunity 
for health care improvement.
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chologist conducted semi-structured individual interviews with 2 clinical experts 
and 30 patients in the UK recruited through general practitioners. Clinical experts 
were asked to identify key concepts attributable to the overactive bladder (symp-
toms). Patients were asked to describe their symptoms and impact on HRQL and 
rate them. All patient responses were coded using code frequency and bother rat-
ings. Results: Seven men, 23 women were interviewed; the majority of patients 
were older than 65 years. 50% of the patients were incontinent. Preliminary analysis 
suggests that OAB affects the patient’s quality of life on several aspect of their 
life: psychological (embarrassment and worry), occupational limitations, domes-
tic (usual activities) and limitations in leisure activities. All patients reported that 
feeling the need to go ‘‘too often’’ to the bathroom (urgency and frequency) led to 
significant limitations such as avoidance of any unplanned activities. HRQL con-
cepts were similar across the different age group. As expected, patients suffering 
from urgency incontinence reported this symptom as being the most impactful, 
especially in terms of embarrassment and worry. cOnclusiOns: Although the 
impact of all OAB symptoms was found to be significant and similar across all 
patients regardless of their age, the greatest impact or burden of OAB was felt and 
reported by wet patients compared to dry patients.
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Objectives: Bladder cancer (BC) is the fourth most common malignancies among 
men and it has high medical costs per-patient from diagnosis until death. Generally 
little is known about the burden BC imposes on patients’ health-related quality 
of life (HRQL) and the literature lacks detailed utility data for economic evalua-
tions in BC. The authors’ goal was to assess the HRQL and health status utility of 
BC patients. MethOds: A cross sectional survey was performed in three hospital 
based urology centres. Adult patients with BC attending routine care were invited to 
participate in the study. Data on demographics, disease history and co-morbidities 
were obtained, validated versions of the EQ-5D and SF-36 generic questionnaires 
were applied. The UK tarrifs were used to calculate EQ-5D score and the SF-36 was 
converted to SF-6D utilities. Disease-specific HRQL was assessed by the FACT-BL 
questionnaire. Results: Altogether 98 patients (males 63.3%) were involved with 
mean age of 66.4 (SD= 8.6) and disease duration of 3.4 (SD= 3.0) years. The SF-36 
physical and mental health summary measures were 62 (SD= 24), 65 (SD= 24), 
respectively, the scores of the 8 domains were comparable to the > 65 years old 
general population’s results. The average SF-6D, EQ-5D and EQ VAS utility scores 
were 0.705 (SD= 0.145), 0.772 (SD= 0.252) and 68.8 (SD= 19.0). The difference of EQ-5D 
score compared to the age-matched population norm was not significant (p= 0.65). 
The FACT-BL physical, social, emotional and functional well-being scores were 
mean 23.1 (SD= 5.4), 20.6 (SD= 5.7), 18.1 (SD= 5.1) and 19.0 (SD= 6.7), the total score 
was 114.0 (SD= 23.5). cOnclusiOns: According to our knowledge this study is the 
first to assess BC patients’ HRQL using diverse preference based measures. Further 
studies involving larger samples might increase our knowledge on the performance 
of these questionnaires in BC subgroups by disease stage, type of treatment and 
urinary diversion.
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Objectives: The reluctance of those with overactive bladder OAB to seek medical 
advice can leave a considerable part of the population untreated, with significant 
costs for society. The present study investigates the burden of individuals who 
experience symptoms of OAB but are not treated. MethOds: Data were taken 
from the 5EU (France, Germany, Italy, Spain, and UK) 2013 National Health and 
Wellness Survey (NHWS), a cross-sectional survey representative of the total adult 
populations in each 5EU market. 62,000 respondents self-reported physician diag-
nosis of various health conditions, including 1,347 who reported symptoms com-
patible with OAB. These respondents were compared to those who didn’t report 
symptoms of OAB. Variables of interest were demographics (age, gender, marital 
status, education, income and employment status), BMI, alcohol and smoke behav-
iour, health-related quality of life (HR-QoL), work productivity and activity impair-
ment (WPAI). Results: The OAB group, compared to the controls, was older (57 
vs. 47 years), with a lower education level (49.14% went to college vs. 54.49%), less 
were in a relationship (26.43% vs. 31.82%), less were employed (35.04% vs. 58.15%), 
more were obese (31.11% vs. 17.22%), they had lower HR-QoL (SF-36v2, PCS: 42.09 
vs. 51.36; MCS: 42.55 vs. 46.25; Utility: 0.62 vs. 0.73), had lower work productivity 
(overall work impairment of 34.46 vs. 20.03) and higher activity impairment (46.07 
vs. 24.35). All differences were significant (p< 0.001). cOnclusiOns: Respondents 
reporting symptoms compatible with OAB but are not treated and would not be 
captured by clinical studies, are significantly worse-off than the rest of the popu-
lation, e.g. in their quality of life, income and work productivity. It is likely that 
undergoing treatment would benefit them and decrease health care costs.
Urinary/Kidney disorders – health care Use & Policy studies
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patients completed the SNM pre-implant evaluation; data from 265 subjects were 
included in EQ-5D or EIQ analyses. Matched paired t-tests compared EQ-5D scores 
and costs from baseline to each follow-up. Results: Baseline mean EQ-5D index 
score (n= 265) was 0.777. Index scores significantly improved (p< 0.05) from base-
line at each follow-up period [3-months (n= 247)= 0.850, 6-months (n= 246)= 0.828, 
and 12-months (n= 232)= 0.839]; the largest improvement in scores (0.073) was at 
3 months. The proportion of patients reporting no problems on the EQ-5D dimen-
sions of Usual Activities, Anxiety/Depression and Pain/Discomfort and Self-Care 
increased from 61.2% (baseline) to 72.0% (12 months); 57.3% to 69.4%; 40.9% to 50.9%, 
and 93.1% to 95.3%, respectively; the Mobility dimension had a non-significant 
decline (68.5% to 66.4%). At baseline, study subjects reported a 3-month average 
expenditure of $228 (US) for durable and disposable medical supplies and health 
service utilization; 74% of the expenditure was attributed to ER, hospitalization and 
outpatient health services use. Expenditures significantly declined (p< 0.05) by an 
average of $163 per 3-month period post-implant. cOnclusiOns: After receiving 
SNM implant, EQ-5D index scores were significantly improved and self-reported 
durable and disposable medical supplies and health service expenses to manage 
OAB were significantly reduced.
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Objectives: 1) To determine what is the utility change for kidney donors from 
before to 3 months after donation; 2) To determine the minimal important differ-
ence (MID) of a decrease (MIDe) in utility for kidney donors. MethOds: We used 
data from a prospective multicenter observational study, measuring the Health 
Related Quality of Life (HRQoL) of kidney donors before and three months after 
transplantation. Utility scores were estimated using the SF-6D and EQ5D. Two 
methods were used to estimate the MIDe: i) the anchor-based method by the 
Global Rating of Change (GRoC) for donors rating their global health “somewhat 
worse” 3 months after donation; ii) the distribution-based method by the standard 
error of measurement (SEM). Results: In total, 211 donors for the EQ-5D and 192 
for the SF-6D completed the questionnaire. Results showed a significant (p< .0001) 
decrease in utility score at three months. The mean (SD) utility score before trans-
plantation was 0.932 (±0.091) with the EQ5D, and 0.834 (±0.085) using the SF-6D, 
and 0.882 (±0.151) and 0.757 (±0.118) respectively at three months with a significant 
decrease (< .0001). Half of donors (53.9%) rated their global health “about the same” 
and 35 (15.4%) “somewhat worse” at follow up. Using the GRoC method, the MIDe 
was -0.113 units for the EQ-5D and -0.128 units for the SF-6D. By the SEM method, 
MIDe was -0.076 for the EQ5D and -0.073 for the SF6D. More than third of patient 
rechead the MIDe using the SEM method. cOnclusiOns: This study showed a 
significant descrease in utility score three months after donation in most donors 
while reporting their global health “about the same”. The MIDe can be used by 
clinician as a threshold to identify donors with a meaningful decrease in utility 
score in a short run after donation.
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Objectives: Urinary incontinence (UI) is a public health issue with a considerable 
social and economic impact. It affects temporarily or permanently about 400 000-500 
000 adults in Hungary. The purpose of our study was to estimate the prevalence, 
consultation rates and treatment behaviour of the adult population. MethOds: 
In 2012 a 15-item questionnaire survey was performed as a part of a mobile 
health unit screening “The comprehensive health test program of Hungary 2010-
2020”. Results: Altogether 13 355 respondents (60.4% female) completed the ques-
tionnaire, the mean age was 40.2 years (SD 12.2). The prevalence rate of UI was 9.7% 
(n= 786) of women and 3.8% (n= 200) of men. Consultation rates were 22.9% (n= 180) 
for women and 32.5% (n= 65) for men. Seventy-three women (40.6%) consulted a 
gynaecologist, 37 (20.5%) a GP, 46 (25.6%) an urologist and 24 (13.3%) consulted more 
than one physicians. Five men (7.7%) consulted a GP, 44 (67.7%) an urologist and 
16 (24.6%) didn’t answer. Among those who consulted a physician 52.2% (n= 94) of 
women and 66.2% (n= 43) of men found solution for their urinary symptoms. In the 
group of respondents who consulted a doctor (n= 245) the most common therapies 
were medications, surgical treatment, absorbent pads or any combination of the 
foregoing. In the group who self-managed their symptoms without consulting a 
doctor (n= 741) absorbent products and/or pelvic muscle training were the most 
frequently applied therapies. cOnclusiOns: Our prevalence results are in line 
with the international UI screenings. We found low medical consulting rates and 
the majority of the respondents having symptoms used self-management tech-
niques for UI.
PUK30
elicitation of health-related QUality of life concePts associated 
with overactive Bladder
Hawken N.A.1, Aballea S.2, Hakimi Z.3, Nazir J.4, Odeyemi I.A.5, Toumi M.2
1Creativ-Ceutical, Luxembourg, Luxembourg, 2Creativ Ceutical, Paris, France, 3Astellas Pharma 
Global Development, Leiden, The Netherlands, 4Astellas Pharma Europe Ltd., Chertsey, UK, 
5Astellas Pharma Europe Limited, Chertsey, UK
Objectives: To review and identify HRQL dimensions in dry and wet OAB patients 
through literature review and patient interviews. MethOds: A literature review 
on OAB HRQL was performed using the EMBASE database. Specialized forums were 
also searched for relevant HRQL issues reported by OAB patients. A trained psy-
